10 Best Long Term Healthcare Stocks to Buy

Page 9 of 9

1. Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Number of Hedge Fund Holders: 43

5-year Revenue Growth: 351.71%

On January 30, H.C. Wainwright raised its price target on Protagonist Therapeutics, Inc. (NASDAQ:PTGX) to $117 from $80 and reiterated a Buy rating. The firm cited the company’s track record in drug development and assigned probability-of-success assumptions across multiple programs, including PN-8047, its IL-4R antagonist, and obesity assets.

In early February, a company director sold 20,000 shares in a transaction valued at approximately $1.7 million, an event monitored by investors alongside ongoing pipeline developments. Protagonist Therapeutics, Inc. (NASDAQ:PTGX) recently reported having two potential late-stage assets, Icotrokinra and Rusfertide, with NDAs submitted in 2025 for plaque psoriasis and polycythemia vera, respectively. The company also expects multiple Phase 2 and Phase 3 readouts across immunology, hematology, and obesity indications. Existing partnerships with Johnson & Johnson and Takeda include milestone and royalty structures that support non-dilutive funding.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) was founded on August 22, 2006, and is headquartered in Newark, California. The company develops peptide-based therapies targeting rare diseases, hematology, and immunology.

While we acknowledge the potential of PTGX as a great healthcare stock to invest in the long term, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PTGX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 9 of 9